The GLP-1 receptor agonist market has become one of the most lucrative segments in pharmaceutical history, with combined revenues exceeding $50 billion in 2025. As patent cliffs approach for key molecules, Indian pharmaceutical companies are uniquely positioned to capture a significant share of this market through biosimilar development and API manufacturing. The opportunity is enormous, but so are the technical and regulatory requirements.
Understanding the Patent Landscape
The timeline for GLP-1 patent expirations varies significantly by molecule and geography, creating a staggered set of market entry opportunities.
Semaglutide (Novo Nordisk’s Ozempic and Wegovy) faces its earliest patent expirations in certain markets starting in 2026. Key formulation and use patents in the European Union and several emerging markets are expiring or can be challenged. However, the US patent landscape is more complex, with Novo Nordisk holding a web of patents that extend protection to 2031-2032 for some formulations. The oral formulation (Rybelsus) has additional patent protection extending even further.
Tirzepatide (Eli Lilly’s Mounjaro and Zepbound) is a newer molecule with patents extending to approximately 2036 in most major markets. While this puts direct biosimilar competition further out, the commercial opportunity is large enough that early investment in manufacturing capabilities is justified.
Liraglutide (Novo Nordisk’s Victoza and Saxenda) has already seen patent expirations in several markets, and biosimilar versions are in various stages of development and approval globally. This serves as a proving ground for companies looking to build GLP-1 biosimilar capabilities.
Why India Is Uniquely Positioned
India’s pharmaceutical industry has several structural advantages that make it the natural leader in GLP-1 biosimilar development.
Peptide manufacturing capability is growing rapidly. While India has historically been strongest in small-molecule generics, several leading companies have invested heavily in peptide synthesis infrastructure over the past five years. Facilities capable of solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis, and hybrid approaches are now operational across Gujarat, Maharashtra, Telangana, and Karnataka.
Cost advantage remains significant. The cost of manufacturing peptide APIs in India is estimated at 40-60% lower than in the US or Europe, driven by lower labor costs, favorable raw material sourcing, and efficient operational models. This cost advantage is critical for biosimilars, where price competition is a primary value proposition.
Regulatory track record provides credibility. Indian companies have a proven history of navigating complex regulatory pathways for biosimilars. Companies like Biocon, Dr. Reddy’s, and Intas have successfully launched biosimilar versions of monoclonal antibodies and other complex biologics in regulated markets, demonstrating the technical and regulatory capabilities needed for GLP-1 biosimilars.
API expertise across the value chain is well-established. India is already the world’s largest supplier of pharmaceutical APIs, and this infrastructure, including analytical laboratories, quality management systems, and supply chain networks, provides a strong foundation for peptide API production.
Regulatory Pathways for GLP-1 Biosimilars
Navigating the regulatory pathway is one of the most complex aspects of bringing a GLP-1 biosimilar to market. The requirements differ by jurisdiction but share common elements.
FDA 351(k) pathway in the United States requires demonstrating biosimilarity through a stepwise approach including analytical characterization, functional assays, animal studies (where relevant), and clinical pharmacokinetic and pharmacodynamic studies. For peptide-based drugs, the FDA may also consider the abbreviated new drug application (ANDA, 505(j)) pathway if the molecule qualifies as a synthetic peptide rather than a biologic. This distinction can significantly impact the development timeline and cost.
EMA biosimilar pathway follows a similar scientific approach but has some procedural differences. The European Medicines Agency has been generally more receptive to biosimilar approvals and has a well-established framework for peptide biosimilars.
CDSCO pathway in India has been evolving to accommodate biosimilar development. The Central Drugs Standard Control Organisation has published guidelines for similar biologics that align broadly with international standards while accounting for the Indian market context.
For exporters targeting multiple markets simultaneously, a platform regulatory strategy that generates data packages acceptable across jurisdictions is the most cost-effective approach. Working with experienced regulatory consultants who understand the nuances of each market is essential.
API Sourcing and Manufacturing Considerations
Manufacturing GLP-1 peptide APIs is technically demanding and requires capabilities that go beyond traditional pharmaceutical manufacturing.
Peptide synthesis for GLP-1 analogs involves assembling chains of 30-40 amino acids with precise sequence fidelity. Both solid-phase peptide synthesis (SPPS) and hybrid approaches are used, with SPPS being more common for these mid-length peptides. The synthesis must achieve high crude purity to minimize downstream purification challenges.
Purification is often the bottleneck in peptide API manufacturing. High-performance liquid chromatography (HPLC) at preparative scale is the standard approach, but the volumes required for commercial-scale GLP-1 production demand significant capital investment in chromatography columns, solvent systems, and waste handling.
Analytical characterization of peptide APIs requires sophisticated instrumentation including mass spectrometry, amino acid analysis, peptide mapping, and circular dichroism spectroscopy. Building and maintaining an analytical laboratory capable of full peptide characterization is a substantial investment but is non-negotiable for regulatory approval.
Cold chain management is critical throughout the API supply chain. Many peptide intermediates and APIs are temperature-sensitive and require controlled storage and shipping conditions. Exporters must have robust cold chain infrastructure and validated shipping procedures.
Market Potential and Financial Opportunity
The financial opportunity in GLP-1 biosimilars is staggering by any measure. The global GLP-1 market, valued at approximately $50 billion in 2025, is projected to reach $150 billion by 2030. Even assuming biosimilar price erosion of 30-50% compared to originator products, the addressable market for biosimilar manufacturers could exceed $50 billion annually.
For Indian pharmaceutical exporters, the most immediate opportunities lie in markets where semaglutide patents are expiring earliest, including parts of Europe, Southeast Asia, the Middle East, and Latin America. These markets combined represent billions of dollars in annual GLP-1 sales and have regulatory frameworks that are receptive to well-developed biosimilar applications.
The API opportunity is equally significant. Even companies that do not develop finished dosage forms can participate by supplying peptide APIs to biosimilar developers worldwide. The global demand for semaglutide API alone could exceed several metric tons annually, representing a multi-billion dollar API market.
What Exporters Should Do Now
Companies looking to capitalize on the GLP-1 biosimilar opportunity should take several concrete steps in the near term.
Invest in peptide manufacturing infrastructure if you have not already. The lead time for building and validating peptide synthesis and purification capabilities is 2-3 years, so investments made now will be ready as key patent expirations arrive.
Build regulatory intelligence for target markets. Understanding the specific requirements, timelines, and precedents in each market will inform development strategy and resource allocation.
Establish analytical capabilities for peptide characterization. Regulatory submissions require comprehensive analytical data packages, and having in-house capabilities accelerates development and reduces costs.
Develop cold chain expertise for peptide APIs and finished products. This is a differentiating capability that many generic pharmaceutical companies currently lack.
Form strategic partnerships with biosimilar developers, CDMOs, and regulatory consultants who have relevant experience in peptide therapeutics.
Key Takeaways
- Semaglutide patent expirations begin in 2026 in some markets, with US patents extending to 2031-2032
- India’s cost advantages, regulatory track record, and growing peptide capabilities make it a natural hub for GLP-1 biosimilar development
- The regulatory pathway requires careful navigation, with different approaches for different markets
- Peptide API manufacturing demands specialized capabilities in synthesis, purification, and analytics
- The addressable market for GLP-1 biosimilars could exceed $50 billion annually by 2030
- Companies should invest now in infrastructure, regulatory intelligence, and strategic partnerships
At KP Life Science, we are actively tracking the GLP-1 biosimilar landscape and building the capabilities needed to serve this rapidly growing market. Our commitment to quality API sourcing and reliable supply chain management positions us well to support partners pursuing GLP-1 biosimilar development across global markets.